Drugs / CTS3497
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06971523 | Dec 2024 → Dec 2028 expected | cancer, lymphoma | CytosinLab Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTS3497 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06971523 ↗ |
| Route | Oral | “Orally via capsules” NCT06971523 ↗ |